![Roche Ireland on X: "FoundationOne®CDx uses a sample of your cancer tissue and FoundationOne®Liquid CDx a blood sample to provide a more complete picture of your cancer and help open up treatment Roche Ireland on X: "FoundationOne®CDx uses a sample of your cancer tissue and FoundationOne®Liquid CDx a blood sample to provide a more complete picture of your cancer and help open up treatment](https://pbs.twimg.com/media/FFsaWjGXMAINXxd.jpg)
Roche Ireland on X: "FoundationOne®CDx uses a sample of your cancer tissue and FoundationOne®Liquid CDx a blood sample to provide a more complete picture of your cancer and help open up treatment
![Foundation Medicine and Pfizer Announce Broad Partnership to Develop Companion Diagnostics for Pfizer's Oncology Portfolio | Business Wire Foundation Medicine and Pfizer Announce Broad Partnership to Develop Companion Diagnostics for Pfizer's Oncology Portfolio | Business Wire](https://mms.businesswire.com/media/20180116005430/en/627351/22/FMI_lockup%C2%AE_left_fire_RGB300ppi_For_BW.jpg)
Foundation Medicine and Pfizer Announce Broad Partnership to Develop Companion Diagnostics for Pfizer's Oncology Portfolio | Business Wire
FoundationOne®CDx Technical Information Foundation Medicine, Inc. 150 Second Street, Cambridge, MA 02141 Phone: 617.418.2200 I
![Foundation Medicine on X: "Now FDA approved as a companion diagnostic for PIQRAY® (alpelisib) to identify PIK3CA mutations, FoundationOne®CDx* may help match even more patients to approved treatments. Learn more: https://t.co/8lbnBl0RPX *Rx Foundation Medicine on X: "Now FDA approved as a companion diagnostic for PIQRAY® (alpelisib) to identify PIK3CA mutations, FoundationOne®CDx* may help match even more patients to approved treatments. Learn more: https://t.co/8lbnBl0RPX *Rx](https://pbs.twimg.com/media/EK-BgfIWsAIYRXm.png)
Foundation Medicine on X: "Now FDA approved as a companion diagnostic for PIQRAY® (alpelisib) to identify PIK3CA mutations, FoundationOne®CDx* may help match even more patients to approved treatments. Learn more: https://t.co/8lbnBl0RPX *Rx
![FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics | Business Wire FDA Approves Foundation Medicine's FoundationOne CDx™, the First and Only Comprehensive Genomic Profiling Test for All Solid Tumors Incorporating Multiple Companion Diagnostics | Business Wire](https://mms.businesswire.com/media/20171130006320/en/627351/5/FMI_lockup%C2%AE_left_fire_RGB300ppi_For_BW.jpg)